Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

NCT01593332 is registered in ClinicalTrials.gov with Mashhad University of Medical Sciences as lead sponsor.

NCT NCT01593332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01593332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Lead sponsor
Mashhad University of Medical Sciences
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2010
Completion date
October 31, 2011
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dmard resistant rheumatoid arthritis